# ABP-450 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/abp-450

> ABP-450, sponsored by AEON Biopharma, Inc. (AEON): 6 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ABP-450 |
| Codes | ABP-450 |
| Sponsor | AEON Biopharma, Inc. (AEON) https://sec-api.dev/companies/aeon/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar 2021: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0001837607-24-000093): "The FDA allowed our Investigational New Drug application, or IND, for ABP-450, supporting our clinical trials in the preventative treatment for migraine, to proceed in October 2020, and we began treating patients in our Phase 2 clinical study beginning in March 2021." https://www.sec.gov/Archives/edgar/data/1837607/000183760724000093/aeon-20240930x10q.htm
- SEC Form 10-Q (accession 0001837607-24-000093): "The FDA allowed our IND for ABP-450, which supports our clinical trials in cervical dystonia, to proceed in October 2020, and we began treating patients in our Phase 2 clinical study beginning in April 2021." https://www.sec.gov/Archives/edgar/data/1837607/000183760724000093/aeon-20240930x10q.htm

### Sep 2022: topline data readout

- Status: completed, met. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2025-08-12.
- SEC Form 10-Q (accession 0001837607-25-000066): "Topline data from the Phase 2 cervical dystonia study, released in September 2022, showed that ABP-450 met all primary endpoints and a number of other key secondary endpoints, supporting the further development of ABP-450 in reducing signs and symptoms associated with cervical dystonia." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000066/aeon-20250630x10q.htm
- SEC Form 10-Q (accession 0001837607-25-000050): "Topline data from the Phase 2 cervical dystonia study, released in September 2022, showed that ABP-450 met all primary endpoints and a number of other key secondary endpoints, supporting the further development of ABP-450 in reducing signs and symptoms associated with cervical dystonia." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000050/aeon-20250331x10q.htm
- SEC Form 10-K (accession 0001837607-25-000022): "Topline data from the Phase 2 cervical dystonia study, released in September 2022, showed that ABP-450 met all primary endpoints and a number of other key secondary endpoints, supporting the further development of ABP-450 in reducing signs and symptoms associated with cervical dystonia." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000022/aeon-20241231x10k.htm
- SEC Form 10-K (accession 0001837607-25-000022): "Topline data from the Phase 2 study, released in September 2022, confirmed that ABP-450 met the primary and a number of other key secondary endpoints, supporting the safety and efficacy of ABP-450 in reducing signs and symptoms associated with cervical dystonia." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000022/aeon-20241231x10k.htm
- SEC Form 10-Q (accession 0001837607-24-000093): "Topline data from the Phase 2 cervical dystonia study, released in September 2022, showed that ABP-450 met all primary endpoints and a number of other key secondary endpoints, supporting the further development of ABP-450 in reducing signs and symptoms associated with cervical dystonia." https://www.sec.gov/Archives/edgar/data/1837607/000183760724000093/aeon-20240930x10q.htm

### May 3, 2024: interim data readout

- Status: completed, missed. Date confidence: exact. Stage: 2.
- First seen 2024-11-13, last confirmed 2025-11-14.
- SEC Form 10-Q (accession 0001837607-25-000085): "On May 3, 2024, the Company announced preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000085/aeon-20250930x10q.htm
- SEC Form 10-Q (accession 0001837607-25-000085): "On May 3, 2024, we announced preliminary top-line results from a planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000085/aeon-20250930x10q.htm
- SEC Form 10-Q (accession 0001837607-25-000066): "On May 3, 2024, the Company announced preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000066/aeon-20250630x10q.htm
- SEC Form 10-Q (accession 0001837607-25-000066): "On May 3, 2024, we announced preliminary top-line results from a planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000066/aeon-20250630x10q.htm
- SEC Form 10-Q (accession 0001837607-25-000050): "On May 3, 2024, the Company announced preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000050/aeon-20250331x10q.htm
- SEC Form 10-Q (accession 0001837607-25-000050): "On May 3, 2024, we announced preliminary top-line results from a planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000050/aeon-20250331x10q.htm
- SEC Form 10-K (accession 0001837607-25-000022): "On May 3, 2024, we announced preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000022/aeon-20241231x10k.htm
- SEC Form 10-K (accession 0001837607-25-000022): "On May 3, 2024, the Company announced preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760725000022/aeon-20241231x10k.htm
- SEC Form 10-Q (accession 0001837607-24-000093): "On May 3, 2024, the Company announced preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760724000093/aeon-20240930x10q.htm
- SEC Form 10-Q (accession 0001837607-24-000093): "On May 3, 2024, we announced preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." https://www.sec.gov/Archives/edgar/data/1837607/000183760724000093/aeon-20240930x10q.htm

### November 14, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-11-14, last confirmed 2025-11-14.
- Press release filed with the SEC (EX-99) (accession 0001837607-25-000084): "AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth" https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm

### November 19, 2025: interim data readout

- Status: scheduled. Date confidence: exact.
- First seen 2025-11-14, last confirmed 2025-11-14.
- Press release filed with the SEC (EX-99) (accession 0001837607-25-000084): "- FDA Type 2a meeting scheduled for November 19, 2025 to review AEON's analytical development plan and initial data -" https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm

### March 30, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-03-30, last confirmed 2026-03-30.
- Press release filed with the SEC (EX-99) (accession 0001837607-26-000018): "AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program" https://www.sec.gov/Archives/edgar/data/1837607/000183760726000018/aeon-20260330xex99d1.htm

Calendar months: [November 2025](https://sec-api.dev/fda-calendar/2025-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/abp-450.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ABP-450 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/abp-450

```bibtex
@misc{secapidev_pdufa_abp_450_20261116,
  title        = {ABP-450 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/abp-450}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_abp_450_20261116","title":"ABP-450 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/abp-450","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
